Honolulu – September 25, 2026 -- Rare Cannabinoid Company has published a new educational guide, "CBD for Menopause: A Guide to Cannabis, THC, CBN and Hemp," aimed at women navigating perimenopause and menopause who are exploring cannabinoids for sleep, mood, focus, appetite and physical comfort.
The guide's central point is that there is no single "menopause cannabinoid." It breaks down seven distinct compounds and their commonly reported uses: CBD for calm and everyday comfort, CBN for nighttime relaxation, THC for deeper relaxation and soreness relief, CBG for physical discomfort and recovery, CBC for mood-oriented formulas, THCV for daytime energy and appetite-conscious routines, and CBDV for social ease and reduced irritability.
Research links hormones to the body's endocannabinoid system, but gaps remain
The guide examines connections between estrogen signaling, endocannabinoid levels and cannabinoid-receptor activity, noting that scientists do not yet fully understand how these relationships shift across perimenopause, menopause and postmenopause. A cited survey of medical cannabis use during perimenopause and postmenopause found participants most often used cannabis for sleep and mood concerns, with many reporting it as helpful -- though researchers behind that survey called for controlled clinical trials to confirm which cannabinoids and dosages actually work.
The guide warns that "menopause gummies" often contain very different ingredients
Products marketed under that label can vary widely in potency and cannabinoid combinations, making it hard for shoppers to know what they're buying. Rare Cannabinoid Company recommends comparing milligrams of each specific cannabinoid per serving rather than total milligrams on the label, and checking for current independent lab reports verifying potency and screening for contaminants.
The company suggests starting with one goal and one modest serving
Its recommended approach: identify the specific concern, choose the cannabinoid that matches it, and begin with a small serving instead of trying multiple new products at once. It also advises consulting a healthcare professional before use for anyone on prescription medications, managing a health condition, considering hormone therapy, or experiencing new or concerning symptoms.
"Menopause is not one symptom, and women do not all experience it in the same way," a company spokesperson said, adding that cannabinoid education should reflect that complexity since no single product or serving works for everyone.
The guide stops short of positioning cannabinoids as a substitute for hormone therapy or other proven menopause treatments, framing current evidence as still developing rather than settled.